Andrew Hill

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3249672/publications.pdf

Version: 2024-02-01

62 papers	1,835 citations	394286 19 h-index	265120 42 g-index
63 all docs	63 docs citations	63 times ranked	2803 citing authors

#	Article	IF	Citations
1	Consolidated plasmid Design for Stabilized Heterologous Production of the complex natural product Siderophore Yersiniabactin. Biotechnology Progress, 2021, 37, e3103.	1.3	3
2	Antibacterial p-Terphenyl with a Rare 2,2â€²-Bithiazole Substructure and Related Compounds Isolated from the Marine-Derived Actinomycete Nocardiopsis sp. HDN154086. Journal of Natural Products, 2021, 84, 1226-1231.	1.5	10
3	Complex natural product production methods and options. Synthetic and Systems Biotechnology, 2021, 6, 1-11.	1.8	10
4	Intranasal Vaccine Delivery Technology for Respiratory Tract Disease Application with a Special Emphasis on Pneumococcal Disease. Vaccines, 2021, 9, 589.	2.1	6
5	Editorial overview: Pharmaceutical biotechnology. Current Opinion in Biotechnology, 2021, 69, vi-viii.	3.3	1
6	Influenza Virus Infects and Depletes Activated Adaptive Immune Responders. Advanced Science, 2021, 8, e2100693.	5.6	7
7	Siderophore natural products as pharmaceutical agents. Current Opinion in Biotechnology, 2021, 69, 242-251.	3.3	23
8	Salicylate Glucoside as a Nontoxic Plant Protectant Alternative to Salicylic Acid. ACS Agricultural Science and Technology, 2021, 1, 515-521.	1.0	1
9	Vaccine Delivery and Immune Response Basics. Methods in Molecular Biology, 2021, 2183, 1-8.	0.4	11
10	Liposomal Dual Delivery of Both Polysaccharide and Protein Antigens. Methods in Molecular Biology, 2021, 2183, 477-487.	0.4	4
11	Improving E. coli by of Bacteriophage Î¦X174 Gene. Methods in Molecular Biology, 2021, 2211, 3-14.	0.4	0
12	A Hybrid Biologicalâ€“Biomaterial Vector for Antigen Delivery. Methods in Molecular Biology, 2021, 2183, 461-475.	0.4	1
13	Liposomal Encapsulation of Polysaccharides (LEPS) as an Effective Vaccine Strategy to Protect Aged Hosts Against S. pneumoniae Infection. Frontiers in Aging, 2021, 2, .	1.2	6
14	Heterologous Biosynthesis of Type II Polyketide Products Using E. coli. ACS Chemical Biology, 2020, 15, 1177-1183.	1.6	31
15	Grafting Activated Graphene Oxide Nanosheets onto Ultrafiltration Membranes Using Polydopamine to Enhance Antifouling Properties. ACS Applied Materials & Interfaces, 2020, 12, 48179-48187.	4.0	24
16	Heterologous biosynthesis as a platform for producing new generation natural products. Current Opinion in Biotechnology, 2020, 66, 123-130.	3.3	19
17	Extended Polysaccharide Analysis within the Liposomal Encapsulation of Polysaccharides System. Materials, 2020, 13, 3320.	1.3	2
18	Monacycliones Gâ€“K and ent-Gephyromycin A, Angucycline Derivatives from the Marine-Derived Streptomyces sp. HDN15129. Journal of Natural Products, 2020, 83, 2749-2755.	1.5	18

#	Article	IF	Citations
19	Flux Balance Analysis for Media Optimization and Genetic Targets to Improve Heterologous Siderophore Production. IScience, 2020, 23, 101016.	1.9	11
20	PEGylated Amine-Functionalized Poly(Îµ-caprolactone) for the Delivery of Plasmid DNA. Materials, 2020, 13, 898.	1.3	8
21	Design Variation of a Dual-Antigen Liposomal Vaccine Carrier System. Materials, 2019, 12, 2809.	1.3	3
22	Antigen delivery format variation and formulation stability through use of a hybrid vector. Vaccine: X, 2019, 1, 100012.	0.9	2
23	Loading and releasing ciprofloxacin in photoactivatable liposomes. Biochemical Engineering Journal, 2019, 141, 43-48.	1.8	17
24	A Transition to Targeted or â€˜Smartâ€™ Vaccines: How Understanding Commensal Colonization Can Lead to Selective Vaccination. Pharmaceutical Medicine, 2018, 32, 95-102.	1.0	0
25	Reconstitution of Kinamycin Biosynthesis within the Heterologous Host Streptomyces albus J1074. Journal of Natural Products, 2018, 81, 72-77.	1.5	35
26	Heterologous erythromycin production across strain and plasmid construction. Biotechnology Progress, 2018, 34, 271-276.	1.3	26
27	Engineering Heterologous Production of Salicylate Glucoside and Glycosylated Variants. Frontiers in Microbiology, 2018, 9, 2241.	1.5	7
28	Engineering a Next-Generation Glycoconjugate-LikeStreptococcus pneumoniaeVaccine. ACS Infectious Diseases, 2018, 4, 1553-1563.	1.8	18
29	Phenotypic Variation during Biofilm Formation: Implications for Anti-Biofilm Therapeutic Design. Materials, 2018, 11, 1086.	1.3	49
30	Constraintâ€based metabolic targets for the improved production of heterologous compounds across molecular classification. AICHE Journal, 2018, 64, 4208-4217.	1.8	1
31	Broadened glycosylation patterning of heterologously produced erythromycin. Biotechnology and Bioengineering, 2018, 115, 2771-2777.	1.7	8
32	Bimodal Targeting Using Sulfonated, Mannosylated <scp>PEI</scp> for Combined Gene Delivery and Photodynamic Therapy. Photochemistry and Photobiology, 2017, 93, 600-608.	1.3	7
33	Comprehensive vaccine design for commensal disease progression. Science Advances, 2017, 3, e1701797.	4.7	28
34	Yersiniabactin metal binding characterization and removal of nickel from industrial wastewater. Biotechnology Progress, 2017, 33, 1548-1554.	1.3	10
35	Increased production of yersiniabactin and an anthranilate analog through media optimization. Biotechnology Progress, 2017, 33, 1193-1200.	1.3	6
36	Yarrowia lipolytica as a Cell Factory for Oleochemical Biotechnology. , 2017, , 459-476.		1

#	Article	IF	Citations
37	Yarrowia lipolytica as a Cell Factory for Oleochemical Biotechnology. , 2017, , 1-19.		1
38	Pressing diseases that represent promising targets for gene therapy. Discovery Medicine, 2017, 24, 313-322.	0.5	4
39	Editorial overview: Pharmaceutical biotechnology: New approaches for dynamic disease targets. Current Opinion in Biotechnology, 2016, 42, vi-vii.	3.3	0
40	Recent progress in therapeutic natural product biosynthesis using Escherichia coli. Current Opinion in Biotechnology, 2016, 42, 7-12.	3.3	23
41	Improved heterologous production of the nonribosomal peptideâ€polyketide siderophore yersiniabactin through metabolic engineering and induction optimization. Biotechnology Progress, 2016, 32, 1412-1417.	1.3	17
42	E. coli metabolic engineering for gram scale production of a plant-based anti-inflammatory agent. Metabolic Engineering, 2016, 38, 382-388.	3.6	34
43	In situ pneumococcal vaccine production and delivery through a hybrid biological-biomaterial vector. Science Advances, 2016, 2, e1600264.	4.7	18
44	Molecular variation of the nonribosomal peptideâ€polyketide siderophore yersiniabactin through biosynthetic and metabolic engineering. Biotechnology and Bioengineering, 2016, 113, 1067-1074.	1.7	8
45	Directed vaccination against pneumococcal disease. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6898-6903.	3.3	39
46	The Continuing Development of E. coli as a Heterologous Host for Complex Natural Product Biosynthesis. Methods in Molecular Biology, 2016, 1401, 121-134.	0.4	13
47	Enhancing vaccine effectiveness with delivery technology. Current Opinion in Biotechnology, 2016, 42, 24-29.	3.3	8
48	Overcoming Gene-Delivery Hurdles: Physiological Considerations for Nonviral Vectors. Trends in Biotechnology, 2016, 34, 91-105.	4.9	132
49	Production of the polyketide 6-deoxyerythronolide B in the heterologous host Bacillus subtilis. Applied Microbiology and Biotechnology, 2016, 100, 1209-1220.	1.7	27
50	Yarrowia lipolytica as a Cell Factory for Oleochemical Biotechnology. , 2016, , 1-18.		2
51	Tailoring pathway modularity in the biosynthesis of erythromycin analogs heterologously engineered in E. coli. Science Advances, 2015, 1, e1500077.	4.7	32
52	Total Biosynthesis and Diverse Applications of the Nonribosomal Peptide-Polyketide Siderophore Yersiniabactin. Applied and Environmental Microbiology, 2015, 81, 5290-5298.	1.4	28
53	Influence of molecular weight upon mannosylated bio-synthetic hybrids for targeted antigen presenting cell gene delivery. Biomaterials, 2015, 58, 103-111.	5.7	11
54	Improved Escherichia coli Bactofection and Cytotoxicity by Heterologous Expression of Bacteriophage Î¦X174 Lysis Gene E. Molecular Pharmaceutics, 2015, 12, 1691-1700.	2.3	10

#	Article	IF	Citations
55	Structureâ€“Function Assessment of Mannosylated Poly(Î²-amino esters) upon Targeted Antigen Presenting Cell Gene Delivery. Biomacromolecules, 2015, 16, 1534-1541.	2.6	24
56	Metabolic engineering of Yarrowia lipolytica for itaconic acid production. Metabolic Engineering, 2015, 32, 66-73.	3.6	119
57	Mannosylated poly(beta-amino esters) for targeted antigen presenting cell immune modulation. Biomaterials, 2015, 37, 333-344.	5.7	43
58	Contemporary approaches for nonviral gene therapy. Discovery Medicine, 2015, 19, 447-54.	0.5	11
59	Harnessing Yarrowia lipolytica lipogenesis to create a platform for lipid and biofuel production. Nature Communications, 2014, 5, 3131.	5.8	488
60	Biomaterials at the interface of nano- and micro-scale vectorâ€“cellular interactions in genetic vaccine design. Journal of Materials Chemistry B, 2014, 2, 8053-8068.	2.9	8
61	Heterologous production of plant-derived isoprenoid products in microbes and the application of metabolic engineering and synthetic biology. Current Opinion in Plant Biology, 2014, 19, 8-13.	3.5	38
62	Porphyrinâ€“phospholipid liposomes permeabilized by near-infrared light. Nature Communications, 2014, 5, 3546.	5.8	282